Trevena Inc TRVN

Healthcare Biotechnology

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).

NDAQ:TRVN - Post by User

Trevena Inc

<< Previous

Bullboard Posts

Next >>

Post by SandMan67on Aug 08, 2020 5:38am

344 Views

Post# 31382229

FDA site

On FDA site as well as 'popular news' sites. Trevena will do a press release Monday (hopefully before open) and the stock should respond for a nice gain. They will also publish qtrly earnings this week. I have a concern they will announce shares being issued to support this new business which could cause a slight dip later in the week but looks like a great long term hold (very good odds they are bought out by big pharma - Pfizer?).
https://www.fda.gov/news-events/press-announcements/fda-approves-new-opioid-intravenous-use-hospitals-other-controlled-clinical-settings

<< Previous

Bullboard Posts

Next >>

One of the strongest contenders to lead Canada’s cannabis market